Available Technologies
# of Displayed Technologies: 10 / 30
Applied Category Filter (Click To Remove): Life & Health Sciences
T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need
As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Schultz, Teri
Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
- College:
- Inventors:
- Licensing Officer: Schultz, Teri
Gene Therapy Approach for Treating Neuropathy
TS-065913 — Gene therapy strategies for treating peripheral neuropathy.
Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart, and adipose tissue. It is a painful, debilitating disease, that is estimated to affect between 20 and 30 million Americans. The number of Americans affected by PN is likely muc…
- College: College of Medicine (COM)
- Inventors: Townsend, Kristy; Blaszkiewicz, Magdalena; Cao, Lei
- Licensing Officer: Schultz, Teri
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Schultz, Teri
Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
- College: College of Medicine (COM)
- Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
- Licensing Officer: Schultz, Teri
Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes.
The Need
Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
- College: College of Medicine (COM)
- Inventors: Kaumaya, Pravin
- Licensing Officer: Schultz, Teri
MicroRNA profile predicts colon cancer prognosis
TS-065453 — The Need:
Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…
- College: College of Medicine (COM)
- Inventors: Croce, Carlo
- Licensing Officer: Schultz, Teri
Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells.
The Need
Current therapies…
- College: College of Medicine (COM)
- Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
- Licensing Officer: Schultz, Teri
Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need
Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
- College: College of Medicine (COM)
- Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
- Licensing Officer: Schultz, Teri
Decision Support Tool for Prevention of Failure to Rescue Events
TS-064718 — A clinical decision support tool for minimizing failure to rescue events at hospitals.
Failure to rescue (FTR) is a serious issue in patient safety and healthcare quality for hospitalized patients. The term implies that rescue is possible, and death is, therefore, a failure. On any given day across the country, two-thirds of deaths in hospitals could be judged as preventable. In 2005,…
- College: OSU Wexner Medical Center
- Inventors: Garvey, Paula; Justice, Stephanie
- Licensing Officer: Schultz, Teri
